LIGAND PHARMACEUTICALS INCORPORATED (NASDAQ:LGND) Files An 8-K Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure.
Pharmaceuticals Incorporated (Ligand or the Company) will be
presenting at Ligands Analyst Day event in New York, New York on
February 28, 2017. The slide presentation is attached as Exhibit
99.1 to this Current Report on Form 8-K and will also be
available under the Investors – News and Events section of
Ligands website at www.ligand.com.
presentation slides attached hereto as Exhibit 99.1, is being
furnished to this Item 7.01 and shall not be deemed filed for
purposes of Section 18 of the Securities Exchange Act of 1934, as
amended (the Exchange Act), or otherwise subject to the
liabilities of that section, and it shall not be deemed
incorporated by reference in any filing under the Securities Act
of 1933, as amended, or under the Exchange Act, whether made
before or after the date hereof, except as expressly set forth by
specific reference in such filing to this Current Report on Form
8-K.
|
(d)
|
Exhibits.
|
|
Exhibit No.
|
Description
|
|
|
99.1
|
Slide Presentation – dated February 28, 2017.
|
|
About LIGAND PHARMACEUTICALS INCORPORATED (NASDAQ:LGND)
Ligand Pharmaceuticals Incorporated (Ligand) is a biopharmaceutical company that focuses on developing and acquiring technologies that help pharmaceutical companies discover and develop medicines. The Company employs research technologies, such as nuclear receptor assays, high throughput computer screening, formulation science, liver targeted pro-drug technologies and antibody discovery technologies to assist companies in their work toward obtaining prescription drug approvals. It has have partnerships and license agreements with over 85 pharmaceutical and biotechnology companies, and over 140 different programs under license with it are in various stages of commercialization and development. Its partners have programs in clinical development targeting seizure, coma, cancer, diabetes, cardiovascular disease, muscle wasting, liver disease and kidney disease, among others. It is developing a small molecule glucagon receptor antagonist for the treatment of Type II diabetes mellitus.
LIGAND PHARMACEUTICALS INCORPORATED (NASDAQ:LGND) Recent Trading Information
LIGAND PHARMACEUTICALS INCORPORATED (NASDAQ:LGND) closed its last trading session down -0.93 at 106.45 with 989,897 shares trading hands.
